Patents by Inventor Keigo Hanada
Keigo Hanada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11744860Abstract: The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-? production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.Type: GrantFiled: April 14, 2017Date of Patent: September 5, 2023Assignees: RIKEN, AMBICION CO., LTD.Inventors: Masaru Taniguchi, Tomokuni Shigeura, Minako Aihara, Keigo Hanada
-
Publication number: 20190134094Abstract: The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-? production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.Type: ApplicationFiled: April 14, 2017Publication date: May 9, 2019Applicants: RIKEN, AMBICION CO., LTD.Inventors: Masaru TANIGUCHI, Tomokuni SHIGEURA, Minako AIHARA, Keigo HANADA
-
Patent number: 8927493Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.Type: GrantFiled: October 8, 2009Date of Patent: January 6, 2015Assignee: Kringle Pharma, Inc.Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
-
Patent number: 8518880Abstract: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.Type: GrantFiled: August 27, 2009Date of Patent: August 27, 2013Assignees: Keio University, Osaka University, Kringle Pharma Inc.Inventors: Hideyuki Okano, Yoshiaki Toyama, Masaya Nakamura, Akio Iwanami, Kazuya Kitamura, Toshikazu Nakamura, Hiroshi Funakoshi, Keigo Hanada
-
Patent number: 8461112Abstract: The present invention relates to an HGF preparation comprising HGF and purified sucrose. The HGF preparation is characterized by being stable even after a long-term storage.Type: GrantFiled: April 29, 2009Date of Patent: June 11, 2013Assignee: Kringle Pharma Inc.Inventors: Kiichi Adachi, Keigo Hanada
-
Publication number: 20120021040Abstract: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.Type: ApplicationFiled: August 27, 2009Publication date: January 26, 2012Applicants: KEIO UNIVERSITY, KRINGLE PHARMA, INC., OSAKA UNIVERSITYInventors: Hideyuki OKANO, Yoshiaki TOYAMA, Masaya NAKAMURA, Akio IWANAMI, Kazuya KITAMURA, Toshikazu NAKAMURA, Hiroshi FUNAKOSHI, Keigo HANADA
-
Publication number: 20110312887Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.Type: ApplicationFiled: October 8, 2009Publication date: December 22, 2011Applicant: KRINGLE PHARMA, INC.Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
-
Publication number: 20100081617Abstract: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.Type: ApplicationFiled: August 27, 2009Publication date: April 1, 2010Applicants: KEIO UNIVERSITY, OSAKA UNIVERSITY, KRINGLE PHARMA, INC.Inventors: Hideyuki OKANO, Yoshiaki TOYAMA, Masaya NAKAMURA, Akio IWANAMI, Kazuya KITAMURA, Toshikazu NAKAMURA, Hiroshi FUNAKOSHI, Keigo HANADA
-
Publication number: 20090233863Abstract: The present invention relates to an HGF preparation comprising HGF and purified sucrose. The HGF preparation is characterized by being stable even after a long-term storage.Type: ApplicationFiled: April 29, 2009Publication date: September 17, 2009Applicant: KRINGLE PHARMA, INC.Inventors: Kiichi Adachi, Keigo Hanada
-
Publication number: 20060128737Abstract: The present invention provides nonsteroidal tetrahydroquinoline derivatives of general formula (I) or salts thereof: (R1, R2, X, Y, Z and m are as defined in claim 1) which show no excessive action on the prostate but show a particularly potent androgen receptor agonistic action on skeletal muscle tissue and bone tissue, as well as pharmaceuticals comprising such derivatives or their salts as active ingredients.Type: ApplicationFiled: June 19, 2003Publication date: June 15, 2006Applicant: KAKEN PHARMACEUTICAL CO., LTD.Inventors: Motonori Miyakawa, Yuji Sumita, Kazuyuki Furuya, Kiyonoshin Ichikawa, Noriko Yamamoto, Seiji Amano, Hiroaki Nejishima, Keigo Hanada
-
Patent number: 7037919Abstract: Tetrahydroquinoline derivatives of general formula (I) or salts thereof, having a specific and strong binding affinity for AR and exhibiting AR agonism or antagonism; and pharmaceutical compositions containing the derivatives or the salts.Type: GrantFiled: October 6, 2000Date of Patent: May 2, 2006Assignee: Kaken Pharmaceutical Co. Ltd.Inventors: Keigo Hanada, Kazuyuki Furuya, Kiyoshi Inoguchi, Motonori Miyakawa, Naoya Nagata
-
Patent number: 6833354Abstract: An object of the present invention is to provide a novel agent for the treatment of bone diseases which can shorten a period for curing various fractures including acceleration of bone formation for bone defect, can improve bone strength of united bones and can also improve reduced bone strength accompanied by various diseases. The agent comprises as an effective ingredient a basic fibroblast growth factor and/or its analogue.Type: GrantFiled: February 17, 1994Date of Patent: December 21, 2004Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Keigo Hanada, Yoshiyuki Hiyama, Makoto Tamura
-
Patent number: 6777427Abstract: Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have therapeutic effects on AR-mediated diseases, particularly by not acting excessively on the prostate as AR agonists, but by showing potent action on skeletal muscle tissue and bone tissue; and pharmaceutical compositions comprising the compounds or the salts as active ingredients:Type: GrantFiled: March 13, 2003Date of Patent: August 17, 2004Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Motonori Miyakawa, Seiji Amano, Misa Kamei, Keigo Hanada, Kazuyuki Furuya, Noriko Yamamoto
-
Publication number: 20030216428Abstract: Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have therapeutic effects on AR-mediated diseases, particularly by not acting excessively on the prostate as AR agonists, but by showing potent action on skeletal muscle tissue and bone tissue; and pharmaceutical compositions comprising the compounds or the salts as active ingredients: 1Type: ApplicationFiled: March 13, 2003Publication date: November 20, 2003Inventors: Motonori Miyakawa, Seiji Amano, Misa Kamei, Keigo Hanada, Kazuyuki Furuya, Noriko Yamamoto
-
Patent number: 5350743Abstract: A bisphosphonic acid derivative of the formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein A is ##STR2## each of R.sup.3 and R.sup.4, which may be the same or different, is (i) a hydrogen atom, (ii) a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group, a C.sub.1-6 alkyl-carbonyl group, a C.sub.2-6 alkenyl-carbonyl group, a C.sub.2-6 alkynyl-carbonyl group R.sup.5 and R.sup.6, which may be the same or different, is a hydrogen atom, a hydroxyl group, a halogen atom, a cyano group, a carbamoyl group, an aralkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted amino group, a C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group;each of m and n is 0 or a positive integer, provided that (m+n) is from 2 to 5; andR is a hydrogen atom, a C.sub.1-8 alkyl group or a C.sub.7-15 aralkyl group.Type: GrantFiled: February 6, 1992Date of Patent: September 27, 1994Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Yoshitaka Ohishi, Makoto Tamura, Mitsuo Hayashida, Satoru Ikegami, Yoshiyuki Hiyama, Takao Awa, Kiyonoshin Ichikawa, Kiyoshi Nomiyama, Keigo Hanada, Mitsuo Mimura